Although TP53 missense mutation induced potential early metastases, TP53 truncating mutation was reported to more negatively correlated with patients’ survival than TP53 missense mutation, [24, 25] so we then evaluated whether this was due to tumor’s sensitivity to chemotherapy. The gene discussed is TP53; the disease is neoplasm.